

Succinoglycan Production by *Rhizobium meliloti* Is Regulated through the ExoS-ChvI Two-Component Regulatory System

HAI-PING CHENG AND GRAHAM C. WALKER*

Biology Department, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

Received 7 July 1997/Accepted 25 October 1997

The *Rhizobium meliloti* *exoS* gene is involved in regulating the production of succinoglycan, which plays a crucial role in the establishment of the symbiosis between *R. meliloti* Rm1021 and its host plant, alfalfa. The *exoS96::Tn5* mutation causes the upregulation of the succinoglycan biosynthetic genes, thereby resulting in the overproduction of succinoglycan. Through cloning and sequencing, we found that the *exoS* gene is a close homolog of the *Agrobacterium tumefaciens* *chvG* gene, which has been proposed to encode the sensor protein of the ChvG-ChvI two-component regulatory system, a member of the EnvZ-OmpR family. Further analyses revealed the existence of a newly discovered *A. tumefaciens* *chvI* homolog located just upstream of the *R. meliloti* *exoS* gene. *R. meliloti* ChvI may serve as the response regulator of ExoS in a two-component regulatory system. By using ExoS-specific antibodies, it was found that the ExoS protein cofractionated with membrane proteins, suggesting that it is located in the cytoplasmic membrane. By using the same antibodies, it was shown that the *exoS96::Tn5* allele encodes an N-terminal truncated derivative of ExoS. The cytoplasmic histidine kinase domain of ExoS was expressed in *Escherichia coli* and purified, as was the *R. meliloti* ChvI protein. The ChvI protein autophosphorylated in the presence of acetylphosphate, and the ExoS cytoplasmic domain fragment autophosphorylated at a histidine residue in the presence of ATP. The ChvI protein was phosphorylated in the presence of ATP only when the histidine kinase domain of ExoS was also present. We propose a model for regulation of succinoglycan production by *R. meliloti* through the ExoS-ChvI two-component regulatory system.

Nodulation of the leguminous plant alfalfa by *Rhizobium meliloti* is a complex developmental process that requires a series of signal exchanges between the host and bacteria (4, 24, 43, 50). Plant flavonoids and bacterial Nod factors are among the best-characterized signals involved in this interorganismal communication process. These plant flavonoids are secreted from the roots and induce Nod factor production by the bacteria (34, 50). The Nod factor then induces root hair curling and initiates nodule development (9, 25). In order for *R. meliloti* cells to successfully invade the nodules they elicit on alfalfa roots, they must be able to synthesize at least one of the following polysaccharides: succinoglycan (13, 14, 40), exopolysaccharide II (15), or a particular 3-deoxy-D-manno-2-octulosonic acid-containing capsular polysaccharide (41, 42). Succinoglycan was the first such exopolysaccharide to be recognized as being crucial for bacterial invasion of nodules (12, 23). Succinoglycan is a polymer composed of repeating octasaccharide subunits containing seven glucose molecules and one galactose molecule with three modifications: succinyl, acetyl, and pyruvyl (1, 19, 38). Succinoglycan can be detected in *R. meliloti* culture supernatants in two size classes: high and low molecular weights (3, 22, 49). A low-molecular-weight oligosaccharide, thought to be a tetramer of the succinoglycan subunits, was reported to partially restore nodule invasion by *exo* mutants when added with the *exo* mutant to the roots of alfalfa plants (3). These observations have led to the suggestion that succinoglycan molecules function as bacterially derived signaling molecules that ensure the successful entry of the bacteria into developing nodules.

Succinoglycan synthesis has been shown to be regulated both in the free-living stage and during symbiosis. In the free-living

stage, succinoglycan production by *R. meliloti* Rm1021 is sensitive to the concentration of ammonia, phosphate, and sulfate present in the growth media (23). For the symbiotic stage, gene fusions have been used to show that the *exo* genes are expressed only in the invasion zone inside the nodule, not in the more mature regions of the nodule (39). This suggests that succinoglycan production is turned off after the bacteria invade the plant cells but before they differentiate into bacteroids.

The first insights into the nature of the regulation of succinoglycan biosynthesis came from the isolation of two succinoglycan-overproducing mutants, those carrying *exoR95::Tn5* and *exoS96::Tn5* (10). In both mutants (36) the transcription of succinoglycan biosynthesis genes is increased, which leads to the overproduction of succinoglycan. This succinoglycan overproduction can be suppressed by transposon insertions in the promoter region of the *exoY* gene (37), which encodes the glycosyl transferase which acts first during succinoglycan biosynthesis (40). Interestingly, the *exoS96* mutant induces nitrogen-fixing nodules on alfalfa roots but the *exoR95* mutant does not. The *exoS* mutant, but not the *exoR* mutant, synthesizes less succinoglycan in the presence of ammonia. The *exoR* gene was sequenced (36), but no homolog has yet been found among genes of known function, which might suggest the mechanism of action of the *exoR* gene product. The *exoS* and the *exoR* genes are located on the *R. meliloti* chromosome and are therefore not linked to the *exo* genes, which are located on the second symbiotic megaplasmid (10).

In this report, we describe the cloning and sequencing of the *R. meliloti* *exoS* gene and our efforts to understand its role in regulating succinoglycan production. We present evidence suggesting that the *exoS* gene encodes a sensor histidine kinase, which acts together with the product of the previously identified *R. meliloti* *chvI* gene to form a two-component regulatory system involved in regulating succinoglycan biosynthesis.

* Corresponding author. Mailing address: 68-633, Biology Department, Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, MA 02139. Phone: (617) 253-6716. Fax: (617) 253-2643. E-mail: gwalker@mit.edu.

MATERIALS AND METHODS

Bacterial strains and growth media. *R. meliloti* Rm7096 carrying the *exoS96::Tn5* mutant allele was derived from wild-type strain Rm1021 (10). The following media were used for the growth of bacteria. Luria-Bertani LB medium was used for *Escherichia coli*, and LB medium with 2.5 mM MgSO₄ and 2.5 mM CaCl₂ was used for *R. meliloti* (13). Mannitol-glutamate-salt (MGS) medium was used in experiments in which succinoglycan production was measured (15). Agarose was used at 1.5% as a solid medium. The following antibiotics were also used at the concentrations indicated: ampicillin, 100 µg/µl; gentamicin, 15 µg/µl; kanamycin, 25 µg/µl; neomycin, 200 µg/µl; and streptomycin, 100 µg/µl.

Cloning and sequencing. The Tn5-derived kanamycin resistance marker and IS50L along with adjacent *R. meliloti* DNA was cloned into plasmid pNEB193 (New England Biolabs, Beverly, Mass.) from *SalI*-digested genomic DNA of the *exoS96::Tn5* mutant and sequenced. The *exoS* gene carrying the 5.3-kb *BglII* fragment of pM13 (10) was cloned into pMCS5 (17) and named pHCS50. The 5.3-kb region was then subcloned into the same vector in three fragments, and nested deletions from opposite directions were made from the subclones. Both strands of DNA of the *exoS* gene and part of the downstream region have been sequenced from these nested deletion constructs manually with a sequencing kit from U.S. Biochemicals (Arlington Heights, Ill.). Parts of the region were also sequenced from pHCS50 with an automated sequencer from Perkin-Elmer ABI (Branchburg, N.J.).

Protein purifications and analyses. All the proteins that were used in this study were cloned into the pET16b vector from Novagen (Madison, Wis.) so that they were expressed with an N-terminal 10-histidine tag attached. The cloned genes were sequenced for confirmation. The overexpressed protein was purified over a nickel column with the HisBind buffer kit from Novagen in accordance with the protocol for cell lysis and subsequent chromatography provided by the manufacturer. Protein products were resolved in polyacrylamide gel with the Hoffer minigel system (San Francisco, Calif.). The concentrations of polyacrylamide gel are indicated in the figure legends.

In the case of the incomplete and complete predicted cytoplasmic domains of ExoS, ExoS_{cyto67} and ExoS_{cyto72}, respectively, both proteins had to be solubilized from inclusion bodies in 6 M urea and purified on a nickel column in 6 M urea. Both purified proteins were renatured as described by Jin et al. (20) by being dialyzed, without stirring for 18 h and then with stirring for 18 h, against the renaturing buffer (20 mM HEPES [pH 7.4], 50 mM KCl, 5 mM dithiothreitol, 50% glycerol).

A membrane protein fraction was prepared in accordance with the protocol described by Chervitz et al. (6) with some modification. Cells from 400 ml of saturated culture were collected and resuspended in 5 ml of lysis buffer. Cells were lysed with a microtip powered by a Sonicator from Heat Systems (Farmingdale N.Y.) at power level 3 with 2.5 s on and 2.5 s off. The total on time was 7 min for *E. coli* cells and 10 min for *R. meliloti* cells. The suspension was then subjected to centrifugation at 7,600 × g for 20 min to remove intact cells; this was followed by centrifugation at 27,000 × g for 20 min to collect membrane protein embedded in the cytoplasmic membrane.

Antibody generation and immunoblot analysis. To obtain polyclonal antibodies against ExoS, the purified cytoplasmic domain of ExoS was resolved on a polyacrylamide gel. The gel was stained in 0.05% Coomassie brilliant blue R-250 prepared in water for 10 min at room temperature with shaking. The lightly stained protein band was then cut out. The gel slices containing protein were used by HRP Inc. (Denver, Pa.) to raise antibodies against ExoS in rabbits. Western blot analyses with ExoS-specific antibodies were conducted by use of the Western Light chemiluminescent detection system from Tropix, Inc. (Bedford, Mass.) according to the manufacturer's instructions.

Autophosphorylation and kinase assay of ExoS_{cyto72}. The purified ExoS_{cyto72} protein was mixed with [γ -³²P]ATP in the reaction buffer (30 mM HEPES [pH 7.4], 10 mM MgCl₂, 5 mM CaCl₂, 50 mM KCl) along with enough unlabeled ATP to give a final concentration of 0.4 µM. The reaction mixture was incubated at room temperature for 10 min. The volumes of the reaction mixtures were reduced under centrifugation in Microcon-10 units (Amicon, Beverly, Mass.). The concentrated, labeled protein was mixed with or without the purified ChvI protein for an additional 5 min before being mixed with an equal volume of 2× loading buffer to stop the reactions. The samples containing ExoS_{cyto72} were boiled before being resolved on gels. The samples containing labeled ChvI protein were not boiled because boiling causes dephosphorylation of phosphorylated ChvI (data not shown). To test the pH stability of phosphorylated ExoS_{cyto72}, the labeled protein was further incubated in 0.1 N HCl or 0.1 N NaOH for an additional 5 min before the addition of 2× loading buffer.

Autophosphorylation assays of ChvI. The autophosphorylation of ChvI protein was assayed as previously described (35), with some modifications. [³²P]acetylphosphate was synthesized with 0.3 U of *E. coli* acetate kinase (Sigma) in a buffer containing 25 mM Tris-HCl (pH 7.4), 60 mM KOAc, 10 mM MgCl₂, and 10 µCi of [γ -³²P]ATP. The reaction was conducted at room temperature for 20 min; acetylphosphate was separated from the enzyme with a Microcon-10 microconcentrator (10,000-molecular-weight cut-off; Amicon), 3 µg of purified His-ChvI protein was added, and the sample was further incubated for 10 min. The phosphorylated ChvI was further incubated with 0.1 N HCl or 0.1 N NaOH for 5 min and neutralized by the addition of 0.1 N NaOH or 0.1 N HCl, respectively.

All reactions were stopped by the addition of equal volumes of 2× sodium dodecyl sulfate loading buffer.

Nucleotide sequence accession number. The GenBank accession number for the DNA sequence of the *exoS* region is AF027298.

RESULTS

Cloning and sequencing the *exoS* gene. To identify the *exoS* gene, we took advantage of the transposon-generated *exoS96::Tn5* allele and the *exoS*⁺ cosmid, pM13 (10). The *exoS*⁺ gene had been localized to a 5.3-kb *BglII* fragment of genomic DNA. We first cloned a *SalI* DNA fragment containing IS50L and the kanamycin resistance gene portion of the Tn5 DNA as well as the flanking *R. meliloti* DNA. Although sequencing this *R. meliloti* DNA did not reveal any homologies to previously sequenced genes, primers derived from this DNA allowed us to obtain a sequence from a subclone carrying the 5.3-kb *BglII* fragment that represented the DNA flanking the opposite side of Tn5 in the mutant strain. Analyses of the DNA sequence revealed a 1,737-bp open reading frame which, in the *exoS96* mutant, is interrupted by the insertion of Tn5 57 bp downstream of the start of the open reading frame. The predicted ExoS protein from this open reading frame was found to have an overall identity of 68% and a similarity of 78% to the *Agrobacterium tumefaciens* ChvG protein (Fig. 1). The sharp drop in the homology between ExoS and ChvG in the region of amino acids 135 to 206 of ExoS could be the result of sequencing artifacts. Compared with our repeatedly sequenced *exoS* DNA sequence, the DNA sequences in the region differ by two +1 frameshifts and two -1 frameshifts. Eliminating the difference would boost the homology between ExoS and ChvG to 78% overall identity. Based on the homology of its predicted kinase domain to that of the *E. coli* PhoR protein, the *A. tumefaciens* ChvG protein has been proposed to be the sensor of the ChvG-ChvI two-component regulatory system (5). The *R. meliloti* ExoS protein has an even higher level of identity with the putative histidine kinase domain of *A. tumefaciens* ChvG protein (Fig. 1). Furthermore, the four most conserved signature sequence patterns, the H, N, D/F, and G boxes that are present in all of the sensor histidine kinases, are also found in these two proteins (Fig. 1). The homology of the *R. meliloti* ExoS protein to the *A. tumefaciens* ChvG protein and other known sensor histidine kinases strongly suggests that ExoS serves as the sensor of a two-component regulatory system that regulates succinoglycan synthesis in *R. meliloti*.

Not only does it appear that ExoS is a sensor kinase, but also the characteristics of its predicted sequence suggest that it belongs to the subset of sensor kinases that are integral membrane proteins and that have substantial periplasmic and cytoplasmic domains. Analyses of the hydrophobicity plots of *R. meliloti* ExoS and *A. tumefaciens* ChvG and of their peptide sequences suggest that they have very similar membrane topologies (data not shown). The domain between the first and second transmembrane domains of the *A. tumefaciens* ChvG protein was determined to be a periplasmic domain based on the isolation of two *TnphoA* fusions (5). The domain between the second and third transmembrane domain contains the highly conserved histidine kinase domain which typically is part of a cytoplasmic domain (5). This N-terminal periplasmic domain and a C-terminal cytoplasmic domain arrangement have been found in many membrane histidine kinase sensor proteins (45). These observations suggest that ExoS similarly has an N-terminal periplasmic domain and a C-terminal cytoplasmic domain which also contains the highly conserved histidine kinase domain.

As we were beginning to sequence DNA in the vicinity of the *exoS* gene in the hopes of identifying a gene encoding the




FIG. 1. Alignment of the putative amino acid sequences of the *R. meliloti* ExoS and *A. tumefaciens* ChvG proteins. The two proteins have an overall identity of 68% and a similarity of 78%. Identical residues are shaded. A possible reason for the sharp drop in homology between residues 135 and 206 is discussed in the text. The putative N terminus of ExoS96 is indicated by an arrow. The four boxes highlight the four most important regions, the H, N, D/F, and G boxes, within the histidine kinase domains of sensor proteins in two-component regulatory systems. The site of phosphorylation is indicated by a triangle. The hatched bars indicate predicted transmembrane domains for ExoS (above the sequence) and ChvG (below the sequence).

corresponding regulator of the two-component system, Østerås et al. (31) published data suggesting that *R. meliloti* Rm1021 contained a two-component regulatory system that is similar to the *A. tumefaciens* ChvG-ChvI two-component regulatory system. They reported the sequence of an *R. meliloti* gene homologous to the *A. tumefaciens* *chvI* gene and that of 360 bp homologous to the 5' end of the *A. tumefaciens* *chvG* gene (27). As in *A. tumefaciens*, the *chvI* gene is located upstream of the *pckA* gene (phosphoenolpyruvate carboxykinase), which was the focus of their study (31). The DNA sequence of the *R. meliloti* *chvI-chvG* intergenic region and the first part of the *chvG* gene determined by Østerås et al. was identical to that of our *exoS* gene, which indicates that the *exoS* gene is the putative *chvG* gene postulated by Østerås et al. Taken together, the combined DNA sequence data indicate that *R. meliloti* encodes a putative two-component regulatory system, ExoS-ChvI, that is closely related to the ChvG-ChvI two-component regulatory system of *A. tumefaciens* (Fig. 2).




FIG. 2. Schematic representation of the organization of the *R. meliloti* ExoS-ChvI and *A. tumefaciens* ChvG-ChvI two-component regulatory systems showing the similarity between the two systems. The predicted transmembrane domains and kinase domains are indicated, as are the two cytoplasmic domains of ExoS (ExoS_{cyto67} and ExoS_{cyto72}) that were used in the study. The lengths of the two arrows indicate the sizes of the cytoplasmic domains. The sites of TnphoA insertions in the *chvG* open reading frame and Tn5 insertion in the *exoS96* mutant are indicated.

***R. meliloti* *exoS96* mutation is suppressed by the *A. tumefaciens* *chvG* gene.** In order to determine whether *R. meliloti* ExoS and *A. tumefaciens* ChvG are functionally related, as suggested by the high level of homology between the two, plasmids carrying either the *A. tumefaciens* *chvG*⁺ gene or the *chvG* gene interrupted by a transposon were introduced into the *R. meliloti* *exoS96* mutant. The levels of succinoglycan production by the resulting strains were then examined on plates. The presence of the *A. tumefaciens* *chvG*⁺ gene caused the reduction of succinoglycan production by the *R. meliloti* *exoS96* mutant, while the transposon-interrupted *chvG* gene did not cause a reduction. This indicates that the *A. tumefaciens* *chvG* gene can suppress the elevated, constitutive level of succinoglycan synthesis observed in an *exoS96* mutant, suggesting that the *R. meliloti* ExoS and *A. tumefaciens* ChvG proteins are functionally interchangeable in *R. meliloti* cells.

Additional evidence that these two proteins are functionally interchangeable came from the work of Østerås et al. They interrupted the cloned *R. meliloti* *chvG* gene, which we have now shown is actually the *exoS* gene, and introduced it into *A. tumefaciens* *chvG* mutants. They found that only the uninterrupted *R. meliloti* *exoS* gene can suppress the mutant phenotype of the *A. tumefaciens* *chvG* mutant, which is sensitive to complex growth media (31). They have also shown that the *R. meliloti* *chvI* gene can suppress the *A. tumefaciens* *chvI* mutant. These results suggest that the heterologous pairs of sensors and response regulators from the two organisms can interact effectively.

ExoS cofractionates with the membrane. In the hope of obtaining sufficient ExoS protein for raising antibodies and for biochemical characterization, we expressed N-terminal His-tagged ExoS in *E. coli* under the control of the T7 promoter. However, after induction no extra protein band corresponding to the predicted molecular weight of ExoS was detected when all the proteins from the induced cells were resolved on a polyacrylamide gel. For increased sensitivity, we separated the proteins from the induced cells into cytoplasmic and membrane fractions. One small extra band having the predicted molecular weight for ExoS could be seen when membrane proteins were separated on a gel. The very small amount of ExoS protein present in the induced cells would have made it difficult to purify enough protein for raising antibodies. There-




FIG. 3. Coomassie blue-stained sodium dodecyl sulfate-polyacrylamide gel of protein samples from the purification of the cytoplasmic domain of ExoS, ExoS_{cyto67}. Lane 1, protein size standards; lanes 2 and 3, total cellular proteins from cells carrying cloning vectors only that were grown under uninduced and induced conditions, respectively; lanes 4 and 5, total cellular proteins from cells carrying the plasmid encoding ExoS_{cyto67} that were grown under uninduced and induced conditions, respectively; lane 6, ExoS_{cyto67} purified over a nickel column.

fore, we instead constructed a plasmid that expressed an N-terminal His-tagged fragment of ExoS, ExoS_{cyto67}, consisting of amino acids 301 to 547, the region constituting most of the predicted histidine kinase domain. This ExoS_{cyto67} protein was produced at high levels but was insoluble. We thus solubilized inclusion bodies in urea, purified the ExoS_{cyto67} protein over a nickel column, resolved the purified protein on a polyacrylamide gel (Fig. 3), and raised antibodies against ExoS with the gel-purified protein. The removal of urea from the purified protein resulted in the precipitation of the protein.

The ExoS-specific antibodies were used to determine the cellular location of the ExoS protein. The total cellular protein of the wild-type strain Rm1021 cells was fractionated into cytoplasmic and membrane proteins after sonication and centrifugation. Equivalent amounts of protein from both fractions were resolved on a polyacrylamide gel, blotted, and probed with ExoS-specific antibodies. As shown in Fig. 4A, one strong band could be seen in the lane containing membrane proteins while one band of much lower intensity migrated at the same position in the lane containing cytoplasmic proteins. This lower-intensity band disappeared when the cytoplasmic protein fraction was subjected to further centrifugation at higher speed, which suggests that the band represents a small amount of ExoS that was associated with the smaller vesicle of the cytoplasmic membrane. These results indicate that ExoS is a




FIG. 4. Cellular distribution of the ExoS protein examined in an immunoblot by using ExoS-specific antibodies. (A) Total cellular proteins from wild-type strain Rm1021 were separated into membrane and cytoplasmic fractions and examined in an immunoblot by using ExoS-specific antibodies. The ExoS protein was found to cofractionate predominantly in the membrane protein fraction. The cross-reacting material in the cytoplasmic protein fraction can be removed by additional high-speed centrifugation, suggesting that it represents ExoS protein which associated with smaller vesicles of cytoplasmic membrane. (B) Membrane proteins from Rm1021 and the *exoS96* mutant were examined in an immunoblot by using ExoS-specific antibodies. Lane 1, wild-type strain proteins; lane 2, *exoS96* mutant proteins. The ExoS band is missing from the lane containing ExoS96 membrane proteins. A faint new band, which is about 1/20 of the intensity of that of ExoS is seen; the band represents a protein that is 5 kDa smaller than ExoS.

membrane protein. This conclusion is consistent with the computer analyses of its putative peptide sequence and with the fact that ExoS cofractionated with membrane proteins in *E. coli*. Thus, it appears that ExoS is a sensor protein located in the cytoplasmic membrane.

exoS96 encodes an N-terminal truncated version of ExoS that cofractionates with the membrane. We were interested in the properties of the *exoS96::Tn5* allele for several reasons. We had initially assumed that it was a null allele because it was caused by a Tn5 insertion and because the *exoS96::Tn5* allele was recessive to *exoS*⁺ carried on pM13 (10), an IncP-based cosmid vector. However, we were unsuccessful in homogenizing a construct of the *exoS* gene in which part of the open reading frame had been replaced by a drug marker, despite several attempts employing minimal medium and the procedures that we have used routinely to generate hundreds of disruptions in *R. meliloti*. We were also unable to interrupt the *chvI* gene by using the same approach. Furthermore, Østerås et al. (31) had reported that they were unsuccessful in homogenizing *chvG::Tn5* mutations into the genome. These observations raised the possibility that the *R. meliloti chvI* and *exoS* genes could not be deleted in a wild-type *R. meliloti* background and that there was something special about the *exoS96* allele.

In the *exoS96::Tn5* mutant, the site of insertion is within the *exoS* open reading frame, 57 bp downstream from the putative start site of the open reading frame. There is an in-frame ATG start codon 135 bp downstream from the beginning of the open reading frame. Since there is an *E. coli* outward-facing promoter within 69 bp of the end of IS50R (7), it seemed possible that the rest of the *exoS* open reading frame could still be transcribed in *R. meliloti* at a low level and then translated. This would result in the synthesis of a truncated ExoS missing the first 45 amino acids at the amino terminus, which would make the ExoS96 protein 5 kDa smaller than the ExoS protein. To examine this possibility, equal amounts of membrane proteins from the *exoS96* mutant were resolved side by side with those from the wild-type strain and were probed with anti-ExoS antibodies (Fig. 4B). For the *exoS96* mutant, the wild-type ExoS band was missing. However there was a band which was about 5 kDa smaller. Its intensity was only 1/20 that of the ExoS band. These results suggest that in the *exoS96* mutant there is a truncated ExoS being made at approximately 1/20 the level of ExoS in the wild-type strain. The size reduction detected in the experiment was consistent with our prediction, which suggests that the ATG located 136 bp inside the *exoS* open reading frame is being used to start the translation. The lower level of the ExoS96 protein compared to the ExoS protein could be due to a low level of transcription, a lack of a proper ribosomal binding site in front of the ATG start codon, or both.

The cytoplasmic domain of the ExoS protein can autophosphorylate at a histidine residue *in vitro* in the presence of ATP. The high level of homology of ExoS to the histidine kinase domains of *E. coli* PhoR and EnvZ strongly suggests that ExoS is a histidine kinase which would autophosphorylate at the conserved histidine residue in the presence of ATP (Fig. 1). To confirm biochemically that ExoS has histidine kinase activities, plasmid pHCT2 was constructed to express the entire cytoplasmic domain of ExoS, ExoS_{cyto72}, with an N-terminal histidine tag (Fig. 2). The ExoS_{cyto72} protein consists of amino acids 281 to 578 from ExoS and forms inclusion bodies when it is overexpressed. It was purified under denaturing conditions and renatured as described in Materials and Methods. When the purified and renatured ExoS_{cyto72} protein was incubated with [γ -³²P]ATP and then resolved on a polyacrylamide gel, a band




FIG. 5. Autoradiograph demonstrating autophosphorylation of the ExoS and ChvI proteins. (A) ExoS_{cyto72} protein autophosphorylates in the presence of [γ -³²P]ATP. The phosphorylated ExoS_{cyto72} loses its phosphate at acidic pH (0.1 N HCl), but not at neutral (buffer; pH 7.4), and alkaline (0.1 N NaOH) pHs. (B) ChvI protein autophosphorylates in the presence of [³²P]acetylphosphate. The phosphorylated ChvI protein loses its phosphate at alkaline pH (0.1 NaOH), but not at neutral (pH 7.4) and acidic (0.1 N HCl) pHs.

appeared on the autoradiograph at the position corresponding to that of ExoS_{cyto72} (Fig. 5). This indicated that the cytoplasmic domain of ExoS can autophosphorylate in the presence of [γ -³²P]ATP, a property which is a characteristic of all tested sensor proteins of two-component regulatory systems.

To test whether a histidine residue is the site of phosphorylation, we examined the stability of phosphorylated ExoS_{cyto72} protein at different pHs (28). Histidyl-phosphate is stable at neutral and alkaline pH but is not stable at acidic pH. The phosphorylated ExoS_{cyto72} protein was further incubated for 5 min at neutral (no additional buffer), acidic (0.1 N hydrochloric acid), or alkaline (0.1 N sodium hydroxide) pH (Fig. 5A). The ExoS_{cyto72} only lost the phosphate label after the acid treatment, an observation consistent with a histidine residue being the site of phosphorylation.

The ChvI protein can autophosphorylate at an aspartate residue in vitro in the presence of acetylphosphate. On the basis of its sequence homology, and because of the genetic analysis of its *A. tumefaciens* homolog, the *R. meliloti* ChvI protein has been said to function as a response regulator in a two-component regulatory system (31). Because many response regulators have been shown to autophosphorylate in the presence of acetylphosphate (26, 45), we decided to test whether the *R. meliloti* ChvI protein shared this distinctive property.

We therefore cloned the *chvI* open reading frame and expressed a derivative carrying an N-terminal oligohistidine tag in *E. coli*. The resulting soluble protein was purified through a nickel column. The purified ChvI protein was then incubated with ³²P-acetylphosphate. As shown in Fig. 5B, the ChvI protein became radiolabeled when [³²P]acetylphosphate was present, suggesting that ChvI can autophosphorylate by using acetylphosphate as the phosphate donor. The phosphorylated ChvI is stable under acidic but not alkaline conditions; this is consistent with the phosphorylation occurring at an acidic residue (35), most likely Asp-52 by analogy to other response regulators. The ChvI protein was not phosphorylated when it was incubated with [γ -³²P]ATP (Fig. 6). All of these results are consistent with ChvI being a response regulator of a two-component regulatory system.

The cytoplasmic domain of ExoS phosphorylates ChvI in vitro. To examine whether the cytoplasmic domain of ExoS has kinase activity, purified ExoS_{cyto72} was tested for its ability to phosphorylate the *R. meliloti* ChvI protein. If the ExoS_{cyto72} protein was first allowed to autophosphorylate by incubation with [γ -³²P]ATP and then was mixed with purified ChvI protein, the ChvI protein became radiolabeled (Fig. 6). The ChvI protein was not labeled if ExoS_{cyto72} was omitted from the




FIG. 6. Autoradiograph showing that ExoS_{cyto72} phosphorylates ChvI protein in the presence of [γ -³²P]ATP. The ChvI protein became phosphorylated only when ExoS_{cyto72} was present as well.

reaction. This indicates that the cytoplasmic domain of ExoS phosphorylates ChvI, which in turn suggests that the ExoS protein is a protein kinase. These results suggest that ExoS is a membrane-bound histidine kinase sensor protein of the ExoS-ChvI two-component regulatory system. As had already been noted (31), the ChvI protein is homologous to response regulators that are phosphorylated on an aspartate residue by the histidine kinase activity of the corresponding sensor protein.

DISCUSSION

Taken together, the data presented in this paper suggest that the *exoS* and *chvI* genes constitute a two-component regulatory system that plays a role in controlling succinoglycan production by *R. meliloti*. The organization of the *exoS* and *chvI* genes is also typical of that of a two-component regulatory system. ExoS contains all four highly conserved protein sequence signatures that have been found in all of the histidine kinase sensor proteins, suggesting that ExoS is also a histidine kinase sensor protein. Our biochemical data support the respective roles for these two proteins that are suggested by analyses of their sequences.

From the computer analyses of its amino acid sequence, ExoS was predicted to be a membrane protein with two transmembrane domains, one close to the N terminus and the other in the middle of the protein. The proposed membrane location of ExoS is consistent with our observations that intact ExoS proteins cofractionated with membrane proteins in both *R. meliloti* and *E. coli*. Since ExoS and *A. tumefaciens* ChvG are functionally exchangeable and have similar hydrophobicity profiles, they most likely have similar membrane topologies. It has been shown that the *A. tumefaciens* ChvG protein has an N-terminal periplasmic domain and a C-terminal cytoplasmic domain (5). The ChvG protein was also proposed to possibly have a third transmembrane domain at the C terminus (5) which ExoS does not have. We have shown that the putative cytoplasmic domain of ExoS has kinase activity. Thus, we propose that ExoS is a histidine kinase sensor protein located in the cytoplasmic membrane that has an N-terminal periplasmic domain and a C-terminal cytoplasmic kinase domain. This is the typical membrane topology for a membrane-bound sensor protein of a two-component regulatory system (45).

Our discoveries concerning *R. meliloti* *exoS* and *chvI*, together with a consideration of other two-component regulatory systems (52), suggest a possible model for the regulation of succinoglycan production by the ExoS-ChvI two-component regulatory system. According to our model, ExoS forms homodimers in the cytoplasmic membrane, and the periplasmic sensor domain of ExoS can switch between activated and non-activated forms. In the presence of an as yet unknown envi-

ronmental signal, the sensor domain stays in the activated form. The sensing of the signal is passed through the membrane by means of a minor structural change in the sensing domain and activates the cytoplasmic kinase. The response regulator, ChvI, is then phosphorylated and activates the transcription of the *exo* genes, thereby increasing production of succinoglycan.

We were initially surprised to find that the *exoS96::Tn5* mutant expresses a smaller ExoS derivative with an N-terminal truncation because the *exoS96::Tn5* allele is recessive to an *exoS⁺* gene carried on an IncP cosmid (10). Since most of the sensors have both kinase and phosphatase activity (2, 29, 45), our data are most easily explained by postulating that it is this truncation that makes ExoS96 into a constitutively active kinase or a defective phosphatase and that results in the consequent overexpression of the *exo* genes and the overproduction of succinoglycan. A consideration of the findings for other two-component regulatory systems, which are described below, provides a possible explanation for the phenotype of the *exoS96* mutant and helped us refine our model.

It has been shown for *E. coli* CheA (45), EnvZ (53), and NtrB (30) and for *A. tumefaciens* VirA (32) that homodimers are the active forms of the two-component sensor proteins. The autophosphorylation of NtrB and EnvZ has been shown to involve *trans*-phosphorylation between subunits of a dimer based on the *in vivo* complementation between wild-type proteins and various mutant forms of the proteins (30, 53). The dimerized form of phosphorylated CheA serves as a phosphate donor, and monomers of phosphorylated CheA have to dimerize before they can serve as phosphate donors (46). The *A. tumefaciens* VirA protein has been shown to form dimers in the cytoplasmic membrane that can be cross-linked on the surfaces of live cells (32). Coexpression of mutant forms of the VirA protein in the wild-type strain inhibits the function of the VirA protein, which suggests the formation of an inactive heterodimer of active and inactive forms of the VirA protein (32).

The amino-terminal peptide leading to the first transmembrane domain and the two transmembrane domains around the periplasmic domain have been found to have a large impact on the sensing ability of the periplasmic domain in sensors of several other two-component regulatory systems. Point mutations in the first transmembrane domain of the *A. tumefaciens* VirA protein (11, 21) can turn VirA into a constitutively active or inactive sensor kinase (11, 33, 48). Replacing either of the two transmembrane domains of the VirA protein with that of the *E. coli* aspartate sensor, Tar, reduces the ability of the VirA protein to respond to its inducer (48). In the nitrate- and nitrite-sensing dual two-component regulatory system, a single substitution of one of the amino acids that precedes the first transmembrane domain made one of the sensors, NarX, stay constitutively active, resulting in upregulation of the relevant genes (51). In the *E. coli* EnvZ-OmpR system, sensor EnvZ has both kinase and phosphatase activities. One particular amino acid substitution at the end of the first transmembrane domain causes EnvZ to lose its phosphatase activity but not its kinase activity (47). The effect of this mutation can be suppressed by a single mutation in the first or the second transmembrane domain of EnvZ (47). These findings suggest that alterations of either of the transmembrane domains that flank the periplasmic domain in this class of sensors can perturb the constitutive state of the sensor and/or its ability to sense the relevant environmental signals.

In the wild-type strain, ExoS has a 30-amino-acid N-terminal segment which precedes the first putative transmembrane domain, which consists of 20 amino acids. Our data suggest that ExoS96 is missing the first 45 amino acids, thereby leaving it

with 5 amino acids of the first transmembrane domain. This shortened transmembrane domain may not be able to anchor the periplasmic domain to the membrane as strongly as the intact one and thus might allow the periplasmic domain of ExoS96 to stay in an active form continuously. The cytoplasmic domain would then also stay active and increase the phosphorylation of ChvI either because its kinase activity is constitutive or because its putative phosphatase activity is diminished. This would lead to the overexpression of the *exo* genes and the overproduction of succinoglycan. We suggest that, when the *exoS96* mutant is complemented with the wild-type *exoS⁺* gene, heterodimers of ExoS and ExoS96 are formed. The interactions between the periplasmic domain of ExoS and ExoS96 restore the ability of the periplasmic domain of ExoS96 to switch between activated and nonactivated forms and suppress the overproduction of succinoglycan observed for the *exoS96* mutant. This hypothesis can be further tested by increasing the amount of ExoS96 in an *exoS⁺* background to see if the production of succinoglycan will be increased or decreased. We are in the process of developing different approaches to test the hypothesis.

Succinoglycan production by *R. meliloti* is also negatively regulated at the transcriptional level by the *exoR* gene, which is involved in sensing ammonia in the media (10). Although, at present, there is no evidence to link ExoR to the ExoS-ChvI two-component regulatory system, extra factors have been found to work with several two-component regulatory systems. For example, a third factor, RcsA, is required for the regulation of *E. coli* capsular polysaccharide production by the *rscC-rscB* two-component regulatory system (16). *A. tumefaciens* ChvE, a periplasmic sugar-binding protein, is required for the *virA-virG* two-component regulatory system to be able to sense an inducer when the inducer is at low concentrations (11). The expression of *eps* and other virulence genes of *Pseudomonas solanacearum* is regulated by a combination of two-component regulatory systems (18).

We are also interested in finding the environmental signal that ExoS senses. Osmotic shock and the disruption of outer membrane proteins have been suggested as being environmental signals that *E. coli* RcsC senses in regulating capsule production in *E. coli* (44) and possibly the expression of a set of outer membrane protein genes, *tolQRA* (8). The amount of ammonia, phosphate, and sulfur in the media can change the rate of succinoglycan production (23). Since the *exoS96* mutant responds to ammonia in the media in the same way as the wild type while the *exoR95* mutant does not respond at all, it is unlikely that ExoS is directly involved in sensing ammonia (10). Identifying the environmental signal(s) sensed by ExoS should help us to gain a better understanding of the regulation of succinoglycan production both in the free-living state and during nodulation and to gain insights into the role(s) of succinoglycan in nodule invasion.

ACKNOWLEDGMENTS

We thank John A. Leigh, Stephen C. Winans, Turlough M. Finan, and Tevor C. Charles for strains, unpublished results, and helpful suggestions. We thank members of this laboratory for many helpful suggestions and critical discussions.

This work is supported by Public Health Service grant GM31030 to G.C.W. from the National Institutes of Health.

REFERENCES

1. Aman, P., M. McNeil, L.-E. Franzen, A. G. Darvill, and P. Albersheim. 1981. Structural elucidation, using HPLC-MS and GLC-MS, of the acidic exopolysaccharide secreted by *Rhizobium meliloti* strain Rm1021. Carbohydr. Res. 95:263-282.
2. Atkinson, M. R., and A. J. Ninfa. 1993. Mutational analysis of the bacterial

- signal-transducing protein kinase/phosphatase nitrogen regulator II (NR_{II} or NtrB). *J. Bacteriol.* **175**:7016–7023.
3. Battisti, L., J. C. Lara, and J. A. Leigh. 1992. Specific oligosaccharide form of the *Rhizobium meliloti* exopolysaccharide promotes nodule invasion in alfalfa. *Proc. Natl. Acad. Sci. USA* **89**:5625–5629.
 4. Brewin, N. J. 1991. Development of the legume root nodule. *Annu. Rev. Cell Biol.* **7**:191–226.
 5. Charles, T. C., and E. W. Nester. 1993. A chromosomally encoded two-component sensory transduction system is required for virulence of *Agrobacterium tumefaciens*. *J. Bacteriol.* **175**:6614–6625.
 6. Chervitz, S. A., C. M. Lin, and J. J. Falke. 1995. Transmembrane signaling by the aspartate receptor: engineered disulfides reveal static regions of the subunit interface. *Biochemistry* **34**:9722–9733.
 7. Clark, A. J., L. Satin, and C. C. Chu. 1994. Transcription of the *Escherichia coli* *recE* gene from a promoter in Tn5 and IS50. *J. Bacteriol.* **176**:7024–7031.
 8. Clavel, T., J. C. Lazzaroni, A. Vianney, and R. Portailier. 1996. Expression of the *tolQRA* genes of *Escherichia coli* K-12 is controlled by the RcsC sensor protein involved in capsule synthesis. *Mol. Microbiol.* **19**:19–25.
 9. Denarie, J., and J. Cullimore. 1993. Lipo-oligosaccharide nodulation factors: a new class of signalling molecules mediating recognition and morphogenesis. *Cell* **74**:951–954.
 10. Doherty, D., J. A. Leigh, J. Glazebrook, and G. C. Walker. 1988. *Rhizobium meliloti* mutants that overproduce the *R. meliloti* acidic Calcofluor-binding exopolysaccharide. *J. Bacteriol.* **170**:4249–4256.
 11. Doty, S. L., M. C. Yu, J. I. Lundin, J. D. Heath, and E. W. Nester. 1996. Mutational analysis of the input domain of the VirA protein of *Agrobacterium tumefaciens*. *J. Bacteriol.* **178**:961–970.
 12. Finan, T. M., A. M. Hirsch, J. A. Leigh, E. Johansen, G. A. Kuldau, S. Deegan, G. C. Walker, and E. R. Signer. 1985. Symbiotic mutants of *Rhizobium meliloti* that uncouple plant from bacterial differentiation. *Cell* **40**:869–877.
 13. Glucksmann, M. A., T. L. Reuber, and G. C. Walker. 1993. Family of glycosyl transferases needed for the synthesis of succinoglycan by *Rhizobium meliloti*. *J. Bacteriol.* **175**:7033–7044.
 14. Glucksmann, M. A., T. L. Reuber, and G. C. Walker. 1993. Genes needed for the modification, polymerization, export, and processing of succinoglycan by *Rhizobium meliloti*: a model for succinoglycan biosynthesis. *J. Bacteriol.* **175**:7045–7055.
 15. González, J. E., B. L. Reuhs, and G. C. Walker. 1996. Low molecular weight EPS II of *Rhizobium meliloti* allows nodule invasion in *Medicago sativa*. *Proc. Natl. Acad. Sci. USA* **93**:8636–8641.
 16. Gottesman, S. 1995. Regulation of capsule synthesis: modification of the two-component paradigm by an accessory unstable regulator, p. 253–262. In J. A. Hoch and T. J. Silhavy (ed.), *Two-component signal transduction*. ASM Press, Washington, D.C.
 17. Hoheisel, J. D. 1994. Creation of a rare cutter multiple cloning site. *Bio-Techniques* **17**:456–459.
 18. Huang, J., B. F. Carney, T. P. Denny, A. K. Weissinger, and M. A. Schell. 1995. A complex network regulates expression of *eps* and other virulence genes of *Pseudomonas solanacearum*. *J. Bacteriol.* **177**:1259–1267.
 19. Jansson, P.-E., L. Kenne, B. Lindberg, H. Ljunggren, U. Ruden, and S. Svensson. 1977. Demonstration of an octasaccharide repeating unit in the extracellular polysaccharide of *R. meliloti* by sequential degradation. *J. Am. Chem. Soc.* **99**:3812–3815.
 20. Jin, S., T. Roitsch, R. G. Ankenbauer, M. P. Gordon, and E. W. Nester. 1990. The VirA protein of *Agrobacterium tumefaciens* is autophosphorylated and is essential for *vir* gene regulation. *J. Bacteriol.* **172**:525–530.
 21. Lee, Y.-W., S. Jin, W.-S. Sim, and E. W. Nester. 1995. Genetic evidence for direct sensing of phenolic compounds by the VirA protein of *Agrobacterium tumefaciens*. *Proc. Natl. Acad. Sci. USA* **92**:12245–12249.
 22. Leigh, J. A., J. W. Reed, J. F. Hanks, A. M. Hirsch, and G. C. Walker. 1987. *Rhizobium meliloti* mutants that fail to succinylate their Calcofluor-binding exopolysaccharide are defective in nodule invasion. *Cell* **51**:579–587.
 23. Leigh, J. A., E. R. Signer, and G. C. Walker. 1985. Exopolysaccharide-deficient mutants of *R. meliloti* that form ineffective nodules. *Proc. Natl. Acad. Sci. USA* **82**:6231–6235.
 24. Long, S. R. 1989. *Rhizobium*-legume nodulation: life together in the underground. *Cell* **56**:203–214.
 25. Long, S. R., and B. J. Staskawicz. 1993. Prokaryotic plant parasites. *Cell* **73**:921–935.
 26. Lukat, G. S., W. R. McCleary, A. M. Stock, and J. B. Stock. 1992. Phosphorylation of bacterial response regulator proteins by low molecular weight phospho-donors. *Proc. Natl. Acad. Sci. USA* **89**:718–722.
 27. Mantis, N. J., and S. C. Winans. 1993. The chromosomal response regulatory gene *chvI* of *Agrobacterium tumefaciens* complements an *Escherichia coli* *phoB* mutation and is required for virulence. *J. Bacteriol.* **175**:6626–6636.
 28. Ninfa, A. J., E. G. Ninfa, A. N. Lupas, A. Stock, B. Magasanik, and J. Stock. 1988. Crosstalk between bacterial chemotaxis signal transduction proteins and regulators of transcription of the Ntr regulon: evidence that nitrogen assimilation and chemotaxis are controlled by a common phosphotransfer mechanism. *Proc. Natl. Acad. Sci. USA* **85**:5492–5496.
 29. Ninfa, A. J., and B. Magasanik. 1986. Covalent modification of the *glnG* product, NRI, by the *glnL* product, NRII, regulates the transcription of the *glnALG* operon in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **83**:5909–5913.
 30. Ninfa, E. G., M. R. Atkinson, E. S. Kamberov, and A. J. Ninfa. 1993. Mechanism of autophosphorylation of *Escherichia coli* nitrogen regulator II (NR_{II} or NtrB): trans-phosphorylation between subunits. *J. Bacteriol.* **175**:7024–7032.
 31. Østerås, M., J. Stanley, and T. M. Finan. 1995. Identification of rhizobium-specific intergenic mosaic elements within an essential two-component regulatory system of *Rhizobium* species. *J. Bacteriol.* **177**:5485–5494.
 32. Pan, S. Q., T. Charles, S. Jin, Z.-L. Wu, and E. W. Nester. 1993. Preformed dimeric state of the sensor protein VirA is involved in plant-*Agrobacterium* signal transduction. *Proc. Natl. Acad. Sci. USA* **90**:9939–9943.
 33. Pazour, G. J., C. N. Ta, and A. Das. 1991. Mutants of *Agrobacterium tumefaciens* with elevated *vir* gene expression. *Proc. Natl. Acad. Sci. USA* **88**:6941–6945.
 34. Peters, N. K., J. W. Frost, and S. R. Long. 1986. A plant flavone, luteolin, induces expression of *Rhizobium meliloti* nodulation genes. *Science* **233**:977–980.
 35. Quon, K. C., G. T. Marczynski, and L. Shapiro. 1996. Cell cycle control by an essential bacterial two-component signal transduction protein. *Cell* **84**:83–93.
 36. Reed, J., J. Glazebrook, and G. C. Walker. 1991. The *exoR* gene of *Rhizobium meliloti* affects RNA levels of other *exo* genes but lacks homology to known transcriptional regulators. *J. Bacteriol.* **173**:3789–3794.
 37. Reed, J. W., M. Capage, and G. C. Walker. 1991. *Rhizobium meliloti* *exoG* and *exoI* mutations affect the ExoX-ExoY system for modulation of exopolysaccharide production. *J. Bacteriol.* **173**:3776–3788.
 38. Reinhold, B. B., S. Y. Chan, T. L. Reuber, A. Marra, G. C. Walker, and V. N. Reinhold. 1994. Detailed structural characterization of succinoglycan, the major exopolysaccharide of *Rhizobium meliloti* Rm1021. *J. Bacteriol.* **176**:1997–2002.
 39. Reuber, T. L., S. Long, and G. C. Walker. 1991. Regulation of *Rhizobium meliloti* *exo* genes in free-living cells and in planta examined by using TnphoA fusions. *J. Bacteriol.* **173**:426–434.
 40. Reuber, T. L., and G. C. Walker. 1993. Biosynthesis of succinoglycan, a symbiotically important exopolysaccharide of *Rhizobium meliloti*. *Cell* **74**:269–280.
 41. Reuhs, B. L. 1996. Acidic capsular polysaccharides (K antigens) of *Rhizobium*, p. 331–335. In G. Stacey, B. Mullin, and P. M. Gresshoff (ed.), *Proceedings of the 8th International Symposium on Molecular Plant-Microbe Interactions*.
 42. Reuhs, B. L., M. N. V. Williams, J. S. Kim, R. W. Carlson, and F. Côté. 1995. Suppression of the Fix⁻ phenotype of *Rhizobium meliloti* *exoB* mutants by *lpsZ* is correlated to a modified expression of the K polysaccharide. *J. Bacteriol.* **177**:4289–4296.
 43. Rolfé, B. G., and P. M. Gresshoff. 1988. Genetic analysis of legume nodule initiation. *Annu. Rev. Plant Physiol. Plant Mol. Biol.* **39**:297–319.
 44. Sledjeski, D. D., and S. Gottesman. 1996. Osmotic shock induction of capsule synthesis in *Escherichia coli* K-12. *J. Bacteriol.* **178**:1204–1206.
 45. Stock, J. B., M. G. Surette, M. Levit, and P. Park. 1995. Two-component signal transduction system: structure-function relationships and mechanisms of catalysis, p. 25–52. In J. A. Hoch and T. J. Silhavy (ed.), *Two-component signal transduction*. ASM Press, Washington, D.C.
 46. Surette, M. G., M. Levit, Y. Liu, G. Lukat, E. G. Ninfa, A. Ninfa, and J. B. Stock. 1996. Dimerization is required for the activity of the protein histidine kinase CheA that mediates signal transduction in bacterial chemotaxis. *J. Biol. Chem.* **271**:939–945.
 47. Tokishita, S.-I., and T. Mizuno. 1994. Transmembrane signal transduction by the *Escherichia coli* osmotic sensor, EnvZ: intermolecular complementation of transmembrane signalling. *Mol. Microbiol.* **13**:435–444.
 48. Turk, S. C. H. J., R. P. van Lange, E. Sonneveld, and P. J. J. Hooykaas. 1993. The chimeric VirA-Tar receptor protein is locked into a highly responsive state. *J. Bacteriol.* **175**:5706–5709.
 49. Urzainqui, A., and G. C. Walker. 1992. Exogenous suppression of the symbiotic deficiencies of *Rhizobium meliloti* *exo* mutants. *J. Bacteriol.* **174**:3403–3406.
 50. van Rhijn, P., and J. Vanderleyden. 1995. The *Rhizobium*-plant symbiosis. *Microbiol. Rev.* **59**:124–142.
 51. Williams, S. B., and V. Stewart. 1997. Nitrate- and nitrite-sensing protein NarX of *Escherichia coli* K-12: mutational analysis of the amino-terminal tail and first transmembrane segment. *J. Bacteriol.* **179**:721–729.
 52. Wurgler-Murphy, S. M., and H. Saito. 1997. Two-component signal transducers and MAPK cascades. *Trends Biochem. Sci.* **22**:172–176.
 53. Yang, Y., and M. Inouye. 1991. Intermolecular complementation between two defective mutant signal-transducing receptors of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **88**:11057–11061.